- •Diabetic Retinopathy
- •Preface
- •Acknowledgments
- •Contents
- •Contributors
- •Pathophysiology of Diabetic Retinopathy
- •1.1 Retinal Anatomy
- •1.1.1 History
- •1.1.2 Anatomy
- •1.1.3 Microanatomy of the Retina Neurons
- •1.1.4 Intercellular Spaces
- •1.1.5 Internal Limiting Membrane
- •1.1.6 Circulation
- •1.1.7 Arteries
- •1.1.8 Veins
- •1.1.9 Capillaries
- •1.2 Hemodynamics, Macular Edema, and Starling’s Law
- •1.3 Biochemical Basis for Diabetic Retinopathy
- •1.3.1 Increased Polyol Pathway Flux
- •1.3.2 Advanced Glycation End Products (AGEs)
- •1.3.3 Activation of Protein Kinase C (PKC)
- •1.3.4 Increased Hexosamine Pathway Flux
- •1.4 Macular Edema
- •1.5 Development of Proliferative Diabetic Retinopathy
- •1.6 Summary of Key Points
- •1.7 Future Directions
- •References
- •Genetics and Diabetic Retinopathy
- •2.1 Background for Clinical Genetics
- •2.2 The Role of Polymorphisms in Genetic Studies
- •2.3 Types of Genetic Study Design
- •2.4 Studies of the Genetics of Diabetic Retinopathy
- •2.4.1 Clinical Studies
- •2.4.2 Molecular Genetic Studies
- •2.4.3 EPO Promoter
- •2.4.4 Aldose Reductase Gene
- •2.4.5 VEGF Gene
- •2.5 Genes in or Near the HLA Locus
- •2.6 Receptor for Advanced Glycation End Products (RAGE) Genes
- •2.7 Endothelial NOS2 and NOS3 Genes
- •2.9 Solute Carrier Family 2 (Facilitated Glucose Transporter), Member 1 Gene (SLC2A1)
- •2.11 Potential Value of Identifying Genetic Associations with Diabetic Retinopathy
- •2.12 Summary of Key Points
- •2.13 Future Directions
- •Glossary
- •References
- •Epidemiology of Diabetic Retinopathy
- •3.1 Introduction and Definitions
- •3.2 Epidemiology of Diabetes Mellitus
- •3.3 Factors Influencing the Prevalence of Diabetes Mellitus
- •3.4 Epidemiology of Diabetic Retinopathy
- •3.5 Diabetes and Visual Loss
- •3.6 Prevalence and Incidence of Diabetic Retinopathy
- •3.7 By Diabetes Type
- •3.8 By Insulin Use
- •3.10 By Duration of Diabetes Mellitus
- •3.11 By Ethnicity
- •3.12 Gender
- •3.13 Age at Onset of Diabetes
- •3.14 Socioeconomic Status and Educational Level
- •3.15 Family History of Diabetes
- •3.16 Changes Over Time
- •3.17 Epidemiology of Diabetic Macular Edema (DME)
- •3.18 Epidemiology of Proliferative Diabetic Retinopathy (PDR)
- •3.19 Socioeconomic Impact of Diabetes
- •3.20 Socioeconomic Impact of Diabetic Retinopathy
- •3.21 Summary of Key Points
- •3.22 Future Directions
- •References
- •Systemic and Ocular Factors Influencing Diabetic Retinopathy
- •4.1 Introduction
- •4.2 Systemic Factors
- •4.2.1 Glycemic Control
- •4.2.1.1 Type 1 Diabetes Mellitus
- •4.2.1.2 Type 2 Diabetes Mellitus
- •4.2.1.3 Rapidity of Improvement in Glycemic Control
- •4.2.2 Glycemic Variability
- •4.2.3 Insulin Use in Type 2 Diabetes
- •4.2.5 Blood Pressure
- •4.2.6 Serum Lipids
- •4.2.7 Anemia
- •4.2.8 Nephropathy
- •4.2.9 Pregnancy
- •4.2.10 Other Systemic Factors
- •4.2.11 Influence on Visual Loss
- •4.3 Effects of Systemic Drugs
- •4.3.1 Diuretics
- •4.3.3 Aldose Reductase Inhibitors
- •4.3.4 Drugs That Target Platelets
- •4.3.5 Statins
- •4.3.6 Protein Kinase C Inhibitors
- •4.3.7 Thiazolidinediones (Glitazones)
- •4.3.8 Miscellaneous Drugs
- •4.4 Ocular Factors Influencing Diabetic Retinopathy
- •4.6 Economic Consequences
- •4.7 Summary of Key Points
- •4.8 Future Directions
- •References
- •Defining Diabetic Retinopathy Severity
- •5.1 Summary of Key Points
- •5.2 Future Directions
- •5.3 Practice Exercises
- •References
- •6.1 Optical Coherence Tomography (OCT)
- •6.2 Heidelberg Retinal Tomograph (HRT)
- •6.3 Retinal Thickness Analyzer (RTA)
- •6.4 Microperimetry
- •6.5 Color Fundus Photography
- •6.6 Fluorescein Angiography
- •6.7 Ultrasonography
- •6.8 Multifocal ERG
- •6.9 Miscellaneous Modalities
- •6.10 Summary of Key Points
- •6.11 Future Directions
- •6.12 Practice Exercises
- •References
- •Diabetic Macular Edema
- •7.1 Epidemiology and Risk Factors
- •7.2 Pathophysiology and Pathoanatomy
- •7.2.1 Anatomy
- •7.3 Physiology
- •7.4 Clinical Definitions
- •7.5 Focal and Diffuse Diabetic Macular Edema
- •7.6 Subclinical Diabetic Macular Edema
- •7.7 Refractory Diabetic Macular Edema
- •7.8 Regressed Diabetic Macular Edema
- •7.9 Recurrent Diabetic Macular Edema
- •7.10 Methods of Detection of Diabetic Macular Edema
- •7.11 Case Report 1
- •7.12 Case Report 2
- •7.13 Other Ancillary Studies in Diabetic Macular Edema
- •7.14 Natural History
- •7.15 Treatments
- •7.15.1 Metabolic Control and Effects of Drugs
- •7.16 Focal/Grid Laser Photocoagulation
- •7.16.1 ETDRS Treatment of CSME
- •7.17 Evolution in Focal/Grid Laser Treatment Since the ETDRS
- •7.18 Macular Thickness Outcomes After Focal/Grid Photocoagulation
- •7.19 Resolution of Lipid Exudates After Focal/Grid Laser Photocoagulation
- •7.20 Inconsistency in Defining Refractory Diabetic Macular Edema
- •7.21 Alternative Forms of Laser Treatment for Diabetic Macular Edema
- •7.22 Peribulbar Triamcinolone Injection
- •7.23 Intravitreal Triamcinolone Injection
- •7.24 Intravitreal Dexamethasone Delivery System
- •7.27 Combined Intravitreal and Peribulbar Triamcinolone and Focal Laser Therapy
- •7.28 Vitrectomy
- •7.29 Supplemental Oxygen and Hyperbaric Oxygenation
- •7.30 Resection of Subfoveal Hard Exudates
- •7.31 Subclinical Diabetic Macular Edema
- •7.32 Cases with Simultaneous Indications for Focal and Scatter Laser Photocoagulation
- •7.34 Factors Influencing Treatment of Diabetic Macular Edema
- •7.35 Sequence of Therapy
- •7.36 Interaction of Cataract Surgery and Diabetic Macular Edema
- •7.37 Summary of Key Points
- •7.38 Future Directions
- •References
- •Diabetic Macular Ischemia
- •8.1 Introduction
- •8.2 Pathogenesis, Anatomy, and Physiology
- •8.3 Natural History
- •8.4 Clinical Evaluation
- •8.5 Clinical Significance of Diabetic Macular Ischemia
- •8.6 Controversies and Conundrums
- •8.7 Summary of Key Points
- •8.8 Future Directions
- •References
- •Treatment of Proliferative Diabetic Retinopathy
- •9.1 Introduction
- •9.2 Laser Photocoagulation
- •9.2.1 Indications
- •9.2.2 PRP Technique
- •9.2.3 Complications
- •9.2.4 Outcome
- •9.3 Intraocular Pharmacological Therapy
- •9.4 Vitreoretinal Surgery
- •9.4.1 Indications
- •9.4.2 Preoperative Management
- •9.4.3 Instrumentation
- •9.4.4 Techniques
- •9.4.5 Postoperative Management
- •9.4.6 Complications
- •9.4.7 General Outcome
- •9.5 Follow-Up Considerations in PDR
- •9.6.1 Cataract and PDR
- •9.6.2 Dense Vitreous Hemorrhage and Untreated PDR
- •9.6.3 Untreated PDR with Diabetic Macular Edema
- •9.6.4 PDR with Severe Fibrovascular Proliferation/Traction Retinal Detachment
- •9.6.5 PDR with Neovascular Glaucoma
- •9.6.6 Conditions Altering the Clinical Course of PDR
- •9.7 Summary of Key Points
- •9.8 Future Directions
- •References
- •Cataract Surgery and Diabetic Retinopathy
- •10.1 Scope of the Problem of Diabetic Retinopathy Concomitant with Surgical Cataract
- •10.2 Visual Outcomes After Cataract Surgery in Patients with Diabetic Retinopathy
- •10.3 Postoperative Course and Special Considerations After Cataract Surgery in Patients with Diabetic Retinopathy
- •10.4 The Influence of Cataract Surgery on Diabetic Retinopathy
- •10.5 The Role of Ancillary Testing in Managing Cataract Surgery in Eyes with Diabetic Retinopathy
- •10.6 Candidate Risk and Protective Factors for Diabetic Macular Edema Induction or Exacerbation Following Cataract Surgery and Suggested Management Actions
- •10.7 The Problem of Adherence to Preferred Practice Guidelines
- •10.8 Management of the Diabetic Eye Without Macular Edema About to Undergo Cataract Surgery
- •10.9 Treatment of Diabetic Macular Edema Detected Before Cataract Surgery When the Macular View Is Clear
- •10.10 Management When Cataract Sufficient to Obscure the Macular View and DME Coexist or When Refractory DME and Cataract Coexist
- •10.11 Patients with Simultaneous Indications for Panretinal Photocoagulation and Cataract Surgery
- •10.12 Management of Cataract in Patients with Diabetic Retinopathy Undergoing Vitrectomy
- •10.13 Influence of Vitrectomy Surgery on Cataract Formation
- •10.15 Postoperative Endophthalmitis in Patients with Diabetic Retinopathy
- •10.16 Summary of Key Points
- •10.17 Future Directions
- •References
- •The Relationship of Diabetic Retinopathy and Glaucoma
- •11.1 Interaction of Diabetes and Glaucoma
- •11.2 Iris and Angle Neovascularization Pathoanatomy and Pathophysiology
- •11.3 Epidemiology
- •11.4 Clinical Detection
- •11.5 Classification
- •11.6 Risk Factors for Iris Neovascularization
- •11.7 Entry Site Neovascularization After Pars Plana Vitrectomy
- •11.8 Anterior Hyaloidal Fibrovascular Proliferation
- •11.9 Treatments for Iris Neovascularization
- •11.10 Modifiers of Behavior of Iris Neovascularization
- •11.11 Management of Neovascular Glaucoma
- •11.12 Summary of Key Points
- •11.13 Future Directions
- •References
- •The Cornea in Diabetes Mellitus
- •12.1 Introduction
- •12.2 Pathophysiology
- •12.3 Anatomy and Morphological Changes
- •12.4 Clinical Manifestations
- •12.5 Ocular Surgery
- •12.6 Treatment of Corneal Disease in Diabetes Mellitus
- •12.7 Conclusion
- •12.8 Summary of Key Points
- •12.9 Future Directions
- •References
- •Optic Nerve Disease in Diabetes Mellitus
- •13.1 Relevant Normal Optic Nerve Anatomy and Physiology
- •13.2 The Effect of Diabetes on the Optic Nerve
- •13.3 Nonarteritic Anterior Ischemic Optic Neuropathy and Diabetes
- •13.4 Diabetic Papillopathy
- •13.5 Disk Edema Associated with Vitreous Traction
- •13.6 Superior Segmental Optic Hypoplasia (Topless Optic Disk Syndrome)
- •13.7 Wolfram Syndrome
- •13.8 Summary of Key Points
- •13.9 Future Directions
- •References
- •Screening for Diabetic Retinopathy
- •14.1 Introduction
- •14.2 Who Does Not Need to Be Screened
- •14.5 Screening with Dilated Ophthalmoscopy by Ophthalmic Technicians or Optometrists
- •14.6 Screening with Dilated Ophthalmoscopy by Ophthalmologists
- •14.7 Screening with Dilated Ophthalmoscopy by Retina Specialists
- •14.8 Photographic Screening
- •14.9 Nonmydriatic Photography
- •14.10 Mydriatic Photography
- •14.11 Risk Factors for Ungradable Photographs
- •14.12 Number of Photographic Fields
- •14.13 Criteria for Referral
- •14.14 Obstacles to the Use of Teleophthalmic Screening Methods
- •14.15 Combination Methods of Screening
- •14.16 Case Yield Rates
- •14.17 Compliance with Recommendation to Be Seen by an Ophthalmologist
- •14.18 Intravenous Fluorescein Angiography and Oral Fluorescein Angioscopy
- •14.19 Automated Fundus Image Interpretation
- •14.20 Subgroups Needing Enhanced Screening Efforts
- •14.21 Screening in Pregnancy
- •14.22 Economic Considerations
- •14.23 Comparisons of the Screening Methods
- •14.24 Accountability of Screening Programs
- •14.25 Summary of Key Points
- •14.26 Future Directions
- •References
- •Practical Concerns with Ethical Dimensions in the Management of Diabetic Retinopathy
- •15.1 Incorporating Ancillary Testing in the Management of Patients with Diabetic Retinopathy
- •15.2.1 Case 1
- •15.2.2 Case 2
- •15.4 Working in a Managed Care Environment (Capitation)
- •15.5 Interactions with Medical Industry
- •15.7 Comanagement of Patients
- •15.9 Summary of Key Points
- •15.10 Future Directions
- •References
- •Clinical Examples in Managing Diabetic Retinopathy
- •16.1.1 Discussion
- •16.2 Case 2: Bilateral Proliferative Diabetic Retinopathy with Acute Vitreous Hemorrhage in One Eye and a Chronic Traction Retinal Detachment in the Other Eye
- •16.2.1 Discussion
- •16.2.2 Opinion 1
- •16.2.3 Opinion 2
- •16.2.4 Opinion 3
- •16.3 Case 3: Sight Threatening Diabetic Retinopathy in a Patient with Concomitant Medical and Socioeconomic Problems
- •16.3.1 Discussion
- •16.4 Case 4: Asymptomatic Retinal Detachment Following Vitrectomy in a Patient Who Has Had Panretinal Laser Photocoagulation
- •16.4.1 Discussion
- •16.5 Case 5: Management of Progressive Vitreous Hemorrhage Following Scatter Photocoagulation for Proliferative Diabetic Retinopathy
- •16.5.1 Discussion
- •16.6.1 Discussion
- •16.7 Case 7: Proliferative Diabetic Retinopathy with Macular Traction and Ischemia
- •16.7.1 Discussion
- •16.8 Case 8: What Is Maximal Focal/Grid Laser Photocoagulation for Diabetic Macular Edema?
- •16.8.1 Definition of the Problem
- •16.8.2 Discussion
- •16.9 Case 9: What Independent Information Does Macular Perfusion Add to Patient Management in Diabetic Retinopathy?
- •16.9.1 Discussion
- •16.10 Case 10: Macular Edema Following Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
- •16.10.1 Discussion
- •16.11 Case 11: Diabetic Macular Edema with a Subfoveal Scar
- •16.11.1 Discussion
- •16.12.1 Definition of the Problem
- •16.12.2 Discussion
- •16.13.1 Definition of the Problem
- •16.13.2 Discussion
- •16.14 Case 14: How Is Diabetic Macular Ischemia Related to Visual Acuity?
- •16.14.1 Definition of the Problem
- •16.14.2 Discussion
- •References
- •Subject Index
2 Genetics and Diabetic Retinopathy |
35 |
|
|
DNA produced by the action of restriction endonucleases, one can deduce the presence or absence of polymorphisms that result in cleavage sites.
Figure 2.4 shows an example of a map of genetic markers, in this case short tandem repeats, corresponding to chromosome 11 and their positional relationship relative to a gene, PAX6, that is critical in ocular embryogenesis. From a study of this figure, it will become evident that one can judiciously choose a polymorphism and examine if it is associated with a disease such as diabetic retinopathy. If there is an association between the polymorphism and the disease phenotype, then neighboring genes to this polymorphism may be candidates for investigation regarding pathogenesis of the disease. Neighboring genes become candidates because segments of DNA tend to be inherited together as a unit. Conversely, if one suspects that a certain gene is important in causing a diabetic retinopathy, one
could choose to study a polymorphism found in close proximity to that gene based on the genetic map and then look for associations of that polymorphism with presence or absence of the disease. In the case of diabetic retinopathy studies, markers for nonproliferative retinopathy (NPDR), proliferative retinopathy (PDR), diabetic macular edema (DME), or presence of any DR have all been studied. The success of such studies depends critically on how reproducible the classification of patients is with regard to disease status. For example, if patients are misclassified as having PDR, a study may spuriously fail to find an association with a genetic marker. Genes conferring susceptibility for NPDR, PDR, DME, and possibly other diabetic retinopathy phenotypes may be distinct.6,20
2.3 Types of Genetic Study Design
Fig. 2.4 Genetic markers called polymorphisms have been mapped throughout the human genome. In this example, short tandem repeat polymorphisms have been mapped on chromosome 11 and are shown in relation to the position of the PAX6 gene. Adapted with permission from Damji et al.1
One common genetic study design is the case-control format. In such a study, a group of patients with diabetic retinopathy or one of its subtypes and a control group with diabetes but no retinopathy are collected. Information is collected regarding some genetic marker for each person in the population sample. Statistical tests are then performed to examine associations of the genetic marker polymorphisms with presence or absence of the disease state. These may be Chi-square tests, odds ratios, likelihood ratios, or others. In theory, this approach could be used to screen many genetic markers at intervals across the entire genome to test for associations, but several methodological constraints limit such a wide net approach.
The genetic marker may have no causal relationship to diabetic retinopathy, but only manifest linkage with the gene that in fact confers risk. If patients with disease and controls are drawn from genetically different populations, a false-positive association may result. Large numbers of statistical tests performed in genome-wide scans can lead to falsepositive associations. In some studies, comparisons of gene frequencies are made between patients with diabetic retinopathy and non-diabetic controls. This can lead to identification of genetic variants
36 |
D.G. Telander et al. |
|
|
associated with vulnerability to diabetes rather than to diabetic retinopathy. To determine genetic variations associated with vulnerability to diabetic retinopathy, it is important to use patients with diabetes but no retinopathy as the control population.21 The results of this type of genetic association study frequently differ.22,23 The reasons offered include different ethnic groups studied and different
criteria for patient selection such as criteria involving renal function.24,25 Thus, given the numerous
pitfalls and discordant results among studies, it is a general rule that confidence in association studies increases in proportion to the number of studies that replicate a given set of findings. Meta-analyses can be useful in deriving a common thread if one exists in frequently discordant genetic studies.22
The Human Genome Project has led to the construction of a genetic map which locates all the known genes and polymorphisms to their particular loci on the 23 pairs of chromosomes (22 pairs of autosomes and 1 pair of sex chromosomes – X and Y). Thus there are 24 genetic submaps, one for each of 22 autosomes and a submap for X and Y. Groups of polymorphisms located on the same chromosomal region tend to be inherited together as a unit and are statistically associated. These are referred to as haplotypes. The HapMap Project is an ongoing international collaboration in which regions of linked polymorphisms are being defined in four international populations.7 Haplotypes are represented by so-called tag SNPs, which are SNPs that are indicators that an entire ensemble of SNPs is present. The ensemble is the haplotype. The tag SNP is the indicator label for a specific haplotype.
A critical tool in the ability to perform linkage analysis is the polymerase chain reaction. This method of taking a small amount of a specific segment of DNA and generating a large amount of identical DNA provides enough material to be detectable and measurable in order to identify the status of a person with regard to presence or absence of a genetic marker. Thus using PCR, each person in a study can be genotyped for a specific allele. The genotype of the allele can be correlated with disease status to determine associations. In PCR, short synthetic pieces of singlestranded DNA called primers are made which flank a specific small region of DNA of interest in the sample from the person. The double-stranded
DNA sample is separated and the primers bind to the region of interest based on their complementary sequences. DNA polymerase and deoxynucleotide triphosphates are then added to the mixture at varying temperatures, resulting in production of new complementary DNA adjacent to the primers at the sequence of interest. Thus two copies of the double-stranded DNA in the region of interest now exist where one had a single copy. The process is repeated many times – 30 times would be typical – producing a billion copies of the DNA sample from a single starter molecule. This larger amount of DNA can then be manipulated, separated, and measured electrophoretically and alleles distinguished. Figure 2.5 illustrates the process of PCR.
Case–control association studies differ from linkage analysis studies, another type of study commonly employed in the investigation of diseases with mendelian inheritance. In a linkage analysis study, a large pedigree with numerous affected members is analyzed using similar molecular genetic techniques. The status of each member of the pedigree with regard to the genetic marker under study is determined. Likewise, the disease status of each member of the family is ascertained. By evaluating the segregation of an allele of the genetic marker with the disease in a pedigree, it is possible to determine the probability that particular alleles are inherited with the disease. Figure 2.6 illustrates the process. To summarize, case–control association analyses examine unrelated population samples. Linkage analyses examine families.
An important method of analysis used in genetics studies of diabetic retinopathy is linkage analysis. In linkage analysis, the expectation is that if an allele makes an important contribution toward disease causation, then the allele should be present in a higher frequency among affected individuals than in the unaffected. Linkage analysis is based on the phenomenon of recombination that occurs during meiosis, or the process of producing sex cells. During meiosis, homologous chromosomes exchange short segments of DNA. The probability that any two small segments of DNA on a chromosome will be separated by this process depends on how far apart they are on the chromosome. The closer the two segments are, the less likely that the segments will be separated by crossing over. Even when there is no known gene directly tied to a disease, this
2 Genetics and Diabetic Retinopathy |
37 |
|
|
a |
b |
c
Fig. 2.5 (a) Schematic representation of the process of polymerase chain reaction. A double-stranded molecule of DNA called the template from a subject under investigation is broken into two single-stranded components by heating. Primers are specifically synthesized which bind to DNA sequences that flank the region of interest (the region in which one is looking for a particular polymorphism). These primers are added to the mixture and anneal to the complementary sequences in the single separated strands of DNA (hybridization).
(b) Polymerase enzymes and deoxynucleotide triphosphates (dNTP) are added to the mixture and new DNA is produced starting at the end of the bound primer. Two double-stranded DNA molecules result. The process is repeated many times to produce enough DNA to manipulate electrophoretically. (c) Schematic of the exponential amplification of DNA through PCR. After 30 cycles, an initial template molecule of DNA results in 1 billion molecules of identical DNA. Adapted with permission from Della12 and Dragon26
concept is useful. One can quantitate how closely a particular genetic marker is to the presence or absence of the disease by examining large numbers of patients and looking for cosegregation of the genetic marker and the presence or absence of the disease. A metric for quantitating how closely a genetic marker is linked to a disease-causing gene is
the LOD score. The LOD score is the logarithm of the odds ratio of linkage of the genetic marker to the disease-causing gene compared to absence of linkage. A LOD score greater than 3 implies an odds ratio exceeding 1000 to 1 in favor of linkage and by convention is taken as evidence of linkage. A LOD score more negative than –2.0 implies odds of 100:1 or
38 |
D.G. Telander et al. |
|
|
Fig. 2.6 Schematic of the approach to associating polymorphisms with disease. At the top, the DNA of patients is amplified with the polymerase chain reaction to produce enough material to allow the investigator to perform electrophoresis. Electrophoresis allows the investigator to determine which allele a given person in a pedigree possesses, because the number of CA repeats affects the position of the DNA on the electrophoretic gel. Thus any given person can be identified genetically (e.g., a person may have alleles A and B or A and C). Without knowledge of the genetic information, clinicians have independently categorized the patient
as having diabetic retinopathy or not. Having diabetic retinopathy is indicated by having the person’s symbol filled in the pedigree. In the illustration, an allele A appears to be inherited with the disease because every affected person in the pedigree possesses an allele A and none of the unaffected persons possess it. However, formal analyses need to be performed which take into account other issues such as type of genetic model (parametric, such as autosomal dominant) used or not (non-parametric or model independent) and frequency of all alleles of the marker compared to controls. Adapted with permission from Damji et al.1
